H.R. 7384 · 118th Congress

Creating Hope Reauthorization Act of 2024

Introduced on Feb 15, 2024 by Michael T. McCaul (R-TX-10). 66 cosponsors, 38 of them from another party. Latest action (Feb 16, 2024): Referred to the Subcommittee on Health.

Stage
Introduced
Introduced
Feb 15, 2024
Cosponsors
66
38 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. 2Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To amend the Federal Food, Drug, and Cosmetic Act to extend the authority of the Secretary of Health and Human Services to issue priority review vouchers to encourage treatments for rare pediatric diseases.

Subjects

  • Child health
  • Drug safety, medical device, and laboratory regulation
  • Prescription drugs

Summary

The Congressional Research Service has not summarized this measure yet.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Michael T. McCaulR-TX-10Sponsor

Democrats · 38

Republicans · 28

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Feb 15, 2024Introduced in House
  2. Feb 15, 2024Introduced in House
  3. Feb 15, 2024 · HouseReferred to the House Committee on Energy and Commerce.
  4. Feb 16, 2024 · HouseReferred to the Subcommittee on Health.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. ACADIA PHARMACEUTICALS8 reports
    $1.4M reported (all issues)
  2. BIOTECHNOLOGY INNOVATION ORGANIZATION7 reports
    $6.7M reported (all issues)
  3. RARE DISEASE COMPANY COALITION6 reports
    $680K reported (all issues)
  4. STEALTH BIOTHERAPEUTICS INC.6 reports
    $390K reported (all issues)
  5. ALLIANCE FOR REGENERATIVE MEDICINE5 reports
    $350K reported (all issues)
  6. IONIS PHARMACEUTICALS, INC.5 reports
    $160K reported (all issues)
  7. bluebird bio, Inc.5 reports
    $420K reported (all issues)
  8. American Cancer Society Cancer Action Network, Inc.4 reports
    $8.1M reported (all issues)
  9. BIOMARIN PHARMACEUTICAL INC.4 reports
    $1.3M reported (all issues)
  10. BRIDGEBIO PHARMA INC.4 reports
    $830K reported (all issues)
  11. CHIESI USA, INC.4 reports
  12. EVERYLIFE FOUNDATION FOR RARE DISEASES4 reports
    $120K reported (all issues)
  13. HARMONY BIOSCIENCES, LLC4 reports
    $600K reported (all issues)Federal contractor: HARMONY BIOSCIENCES LLC$614.4K in contracts, FY2026AI match · 100%
  14. NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.)4 reports
    $5.7M reported (all issues)
  15. PTC THERAPEUTICS, INC.4 reports
    $760K reported (all issues)
  16. The Leukemia & Lymphoma Society4 reports
    $1M reported (all issues)
  17. ASSOCIATION FOR CLINICAL ONCOLOGY3 reports
    $750K reported (all issues)
  18. Bayer Corporation (consolidated report)3 reports
    $6.2M reported (all issues)
  19. CURE SMA3 reports
    $225K reported (all issues)
  20. JOHNSON & JOHNSON SERVICES, INC.3 reports
    $5M reported (all issues)
  21. Muscular Dystrophy Association, Inc.3 reports
    $210K reported (all issues)Federal contractor: MUSCULAR DYSTROPHY ASSOCIATION INC$315K in contracts, FY2026AI match · 100%
  22. Travere Therapeutics3 reports
    $360K reported (all issues)Federal contractor: TRAVERE THERAPEUTICS, INC.$323.9K in contracts, FY2026AI match · 100%
  23. Astria Therapeutics, Inc.2 reports
    $80K reported (all issues)
  24. Cystic Fibrosis Foundation2 reports
    $220K reported (all issues)
  25. Fulcrum Therapeutics2 reports
    $120K reported (all issues)
  26. National Bleeding Disorder Foundation (fka National Hemophilia Foundation)2 reports
    $100K reported (all issues)
  27. Rocket Pharmaceuticals, Inc.2 reports
    $60K reported (all issues)
  28. SHIONOGI INC.2 reports
    $170K reported (all issues)Federal contractor: SHIONOGI INC$156.1M in contracts, FY2026AI match · 100%
  29. SOLENO THERAPEUTICS, INC.2 reports
    $110K reported (all issues)
  30. ULTRAGENYX PHARMACEUTICAL INC.2 reports
  31. Epilepsy Foundation1 report
    $60K reported (all issues)
  32. Life Sciences Pennsylvania1 report
  33. National Hemophilia Foundation1 report
    $50K reported (all issues)
  34. PFIZER INC.1 report
    $1.1M reported (all issues)Federal contractor: PFIZER INCAI match · 100%

Reports filed in 2024, 2025.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 9, 2026 · loaded Oct 9, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 9, 2026 · loaded Oct 9, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.